Recent News

• 06.11.2025 - Treatment of Refractory SLE with Off-the-Shelf iPSC-derived Anti-CD19 CAR T-cell Therapy
• 06.11.2025 - Fate Therapeutics Announces Updated Clinical Data for FT819 Off-the-shelf CAR T-cell Product Candidate Demonstrating Durability of Drug-free Remission for Severe Lupus Nephritis at EULAR 2025 Congress
• 05.30.2025 - Fate Therapeutics Appoints Matthew Abernethy, M.B.A., to its Board of Directors
• 05.30.2025 - Fate Therapeutics Appoints Matthew Abernethy, M.B.A., to its Board of Directors
• 05.28.2025 - Fate Therapeutics Announces Phase 1 Data Presentation of FT819 Off-the-Shelf CAR T-cell Product Candidate for SLE at EULAR 2025 Congress
• 05.28.2025 - Fate Therapeutics Announces Phase 1 Data Presentation of FT819 Off-the-Shelf CAR T-cell Product Candidate for SLE at EULAR 2025 Congress

Recent Filings

• 06.04.2025 - S-8 Securities to be offered to employees in employee benefit plans
• 05.30.2025 - 4 Statement of changes in beneficial ownership of securities
• 05.30.2025 - 4 Statement of changes in beneficial ownership of securities
• 05.30.2025 - 3 Initial statement of beneficial ownership of securities
• 05.30.2025 - 4 Statement of changes in beneficial ownership of securities
• 05.30.2025 - 4 Statement of changes in beneficial ownership of securities
• 05.30.2025 - 4 Statement of changes in beneficial ownership of securities
• 05.30.2025 - 4 Statement of changes in beneficial ownership of securities
• 05.30.2025 - 4 Statement of changes in beneficial ownership of securities
• 05.30.2025 - 4 Statement of changes in beneficial ownership of securities